These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26897036)

  • 1. Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis.
    Li X; Zhao H; Gu J; Zheng L
    World J Surg Oncol; 2016 Feb; 14(1):38. PubMed ID: 26897036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
    Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
    J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of microRNA-21 in pancreatic ductal adenocarcinoma: a meta-analysis.
    Hu GY; Tao F; Wang W; Ji KW
    World J Surg Oncol; 2016 Mar; 14():82. PubMed ID: 26969625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J; Takei H; Ro JY; Lowery-Nordberg M
    Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma.
    Koperek O; Aumayr K; Schindl M; Werba G; Soleiman A; Schoppmann S; Sahora K; Birner P
    APMIS; 2014 Jun; 122(6):476-81. PubMed ID: 24164699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
    Wang Y; He L; Cheng Y
    Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
    Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
    Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
    Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
    Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry.
    Bachmann K; Neumann A; Hinsch A; Nentwich MF; El Gammal AT; Vashist Y; Perez D; Bockhorn M; Izbicki JR; Mann O
    J Surg Oncol; 2015 Mar; 111(3):316-23. PubMed ID: 25470788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
    Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
    Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.